Menu Search
Equities

3D Medicines Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
1244:HKG.HZ

3D Medicines Inc

Actions
  • Price (HKD)4.47
  • Today's Change-0.14 / -3.04%
  • Shares traded15.50k
  • 1 Year change+54.14%
  • Beta--
Data delayed at least 15 minutes, as of Feb 06 2026 07:55 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

3D Medicines Inc is an investment holding company principally engaged in the research and development of oncology therapies. The Company's product pipeline includes small-molecule targeted drugs, single/bispecific antibodies, immune checkpoint inhibitors, and peptide vaccines, spanning multiple stages of cancer treatment. The Company's drug candidates include envafolimab, 3D189, 3D185, and 3D124. The Company is also engaged in the development of messenger ribonucleic acid (mRNA) products through mRNA research and development platform and oncology genomics big-data artificial intelligence (AI) analysis platform. The Company primarily conducts its businesses in domestic market.

  • Revenue in HKD (TTM)504.64m
  • Net income in HKD-189.64m
  • Incorporated2018
  • Employees183.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.